Stock Track | Rhythm Pharmaceuticals Soars 6.55% After Beating Q3 2024 Earnings Estimates

Stock Track11-06

Shares of Rhythm Pharmaceuticals Inc. (NASDAQ: RYTM) surged 6.55% on Monday, November 5th, after the biopharmaceutical company reported better-than-expected financial results for the third quarter of 2024.

Rhythm Pharmaceuticals announced a quarterly loss of $0.73 per share, beating analysts' consensus estimate of a $0.82 per share loss. The company also reported revenue of $33.251 million, surpassing the average analyst expectation of $32.517 million. Compared to the same period last year, Rhythm's revenue increased by an impressive 47.76%.

The strong Q3 performance highlights the growing demand for Rhythm's products and demonstrates the company's ability to exceed market expectations. Investors reacted positively to the earnings beat, driving RYTM's stock price up by 6.55% on the day of the announcement.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1190694542?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-06 05:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1190694542","market":"us","top_or_hot":-1,"title":"Stock Track | Rhythm Pharmaceuticals Soars 6.55% After Beating Q3 2024 Earnings Estimates","media":"Stock Track","content":"<p>Shares of Rhythm Pharmaceuticals Inc. (NASDAQ: RYTM) surged 6.55% on Monday, November 5th, after the biopharmaceutical company reported better-than-expected financial results for the third quarter of 2024.</p>\n\n<p>Rhythm Pharmaceuticals announced a quarterly loss of $0.73 per share, beating analysts' consensus estimate of a $0.82 per share loss. The company also reported revenue of $33.251 million, surpassing the average analyst expectation of $32.517 million. Compared to the same period last year, Rhythm's revenue increased by an impressive 47.76%.</p>\n\n<p>The strong Q3 performance highlights the growing demand for Rhythm's products and demonstrates the company's ability to exceed market expectations. Investors reacted positively to the earnings beat, driving RYTM's stock price up by 6.55% on the day of the announcement.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Rhythm Pharmaceuticals Soars 6.55% After Beating Q3 2024 Earnings Estimates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Rhythm Pharmaceuticals Soars 6.55% After Beating Q3 2024 Earnings Estimates\n</h2>\n\n<h4 class=\"meta\">\n\n2024-11-06 05:10 北京时间&nbsp;&nbsp;&nbsp;<strong>Stock Track</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Rhythm Pharmaceuticals Inc. (NASDAQ: RYTM) surged 6.55% on Monday, November 5th, after the biopharmaceutical company reported better-than-expected financial results for the third quarter of ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RYTM","symbol_name":"Rhythm Pharmaceuticals Inc.","start_time":0,"source_url":"","article_id":"1190694542","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1190694542","pubTimestamp":1730841034,"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Rhythm Pharmaceuticals Inc.  surged 6.55% on Monday, November 5th, after the biopharmaceutical company reported better-than-expected financial results for the third quarter of 2024.Rhythm Pharmaceuticals announced a quarterly loss of $0.73 per share, beating analysts' consensus estimate of a $0.82 per share loss. The company also reported revenue of $33.251 million, surpassing the average analyst expectation of $32.517 million. Compared to the same period last year, Rhythm's revenue in","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"RYTM":"Rhythm Pharmaceuticals Inc."},"translate_title":"Rhythm Pharmaceuticals超出2024年第三季度盈利预期后股价飙升6.55%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RYTM":1},"content_text":"Shares of Rhythm Pharmaceuticals Inc. (NASDAQ: RYTM) surged 6.55% on Monday, November 5th, after the biopharmaceutical company reported better-than-expected financial results for the third quarter of 2024.\nRhythm Pharmaceuticals announced a quarterly loss of $0.73 per share, beating analysts' consensus estimate of a $0.82 per share loss. The company also reported revenue of $33.251 million, surpassing the average analyst expectation of $32.517 million. Compared to the same period last year, Rhythm's revenue increased by an impressive 47.76%.\nThe strong Q3 performance highlights the growing demand for Rhythm's products and demonstrates the company's ability to exceed market expectations. Investors reacted positively to the earnings beat, driving RYTM's stock price up by 6.55% on the day of the announcement.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1190694542"}